96.76 <%= Resources.Global.txtDown %>
Updated 21/09/2018
Change % -1.10% Stock price decreasing
Change -1.08 Stock price decreasing
Volume 537,673
High 98.76
Low 96.24
Open 97.50
ISIN BE0003818359
Prev close 97.84
# of shares 54.30M
Market cap 5,253.98M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  96.76 -2.9% Stock price decreasing 7.4% Stock price increasing 13.1% Stock price increasing 17.8% Stock price increasing 16.2% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
24 September 2018 01:42:14
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB1 - 2018-09-24 02:42:14 - 2018-09-24 01:42:14 - 1000 - Website: OKAY